B
Beacon Therapeutics
Gene therapy solutions for restoring vision in patients with blinding retinal diseases
About Beacon Therapeutics
Beacon Therapeutics is a startup that operates in the healthcare sector, specifically focusing on ophthalmic gene therapy. In simpler terms, the company works on developing treatments for eye diseases that can lead to blindness. Their primary focus is on retinal diseases, which are conditions that damage the retina, a part of the eye that is crucial for vision.
Read full description
The company was founded in 2023 with the mission to restore and improve the vision of patients suffering from both common and rare retinal diseases. Beacon Therapeutics' business model revolves around the development and commercialization of gene therapies. They have a late-stage development candidate for treating X-linked retinitis pigmentosa (XLRP), a genetic condition that causes progressive vision loss. In addition to this, they are also working on two innovative preclinical programs for other prevalent and rare blinding diseases.
Their clients are primarily patients suffering from these retinal diseases. By providing effective gene therapies, Beacon Therapeutics aims to offer a solution to these patients, thereby improving their quality of life.
The company generates revenue by developing and selling these gene therapies. As they progress through the stages of clinical trials and receive approval for their therapies, they can commercialize these treatments, providing a new revenue stream.
In conclusion, Beacon Therapeutics is a promising startup in the healthcare sector, focusing on ophthalmic gene therapy to treat retinal diseases. Their innovative approach to treating these conditions could potentially revolutionize the way these diseases are managed, offering hope to patients worldwide.
At a glance
- Status
- Operational
- Founded
- 2023
- Headquarters
- Alachua, United States
- Employees
- 96
- Open positions
- 1
- Dealroom signal
- 81.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Disease, Rumoured $1B, Biotech and Pharma, DT and LS, uk is8 life sciences, UKSU, UKSU2010, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Beacon Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Jan 2026 | $75M | $850M | Advent Life Sciences · Retinal Degeneration Fund · Forbion Capital Partners · Syncona | ↗ |
| SERIES BOther financing | Jul 2024 | $170M | $680M | Advent Life Sciences · Syncona · TCGX · Oxford Science Enterprises | ↗ |
Growth signals
Latest recorded traffic for Beacon Therapeutics is 7.5K monthly website visits, down 12.8% over the last three months. Beacon Therapeutics's team grew 5.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Syncona
Oxford Science Enterprises
Forbion Capital Partners
Advent Life Sciences
TCGX
Series B and later2 investors entered at this stage
Goldman Sachs
Retinal Degeneration Fund
Other known investors1 additional known investor
University of Oxford
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Beacon Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Beacon Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.